Optimistic Buy Rating for Abivax SA Driven by Promising Phase 3 Developments and Market Potential

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ABVX stock, giving a Buy rating today.

Sam Slutsky has given his Buy rating due to a combination of factors surrounding Abivax SA’s ongoing clinical developments and market potential. The completion of patient enrollment in the Phase 3 ABTECT program for obefazimod, targeting moderate-to-severe ulcerative colitis, marks a significant milestone. The anticipation of topline data by Q3 2025, which is expected to be positive, could lead to substantial stock appreciation, especially given the current low valuation of ABVX compared to historical industry benchmarks.
Moreover, the Phase 3 study’s design and initial blinded response rates align with the successful outcomes observed in the Phase 2b study, suggesting a promising outlook. The clinical response rates and the strategic planning for future data releases and regulatory submissions further bolster confidence in the company’s trajectory. These elements, combined with the potential market impact of obefazimod, underpin Slutsky’s optimistic Buy rating for Abivax SA Sponsored ADR.

In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $33.00 price target.